Biotech

The Food and Drug Administration’s top vaccine regulator is pushing new limits on how vaccines win approval. The tougher standards could cloud prospects for vaccine makers and rattle investors in major healthcare and biotech names. Center for Biologics Evaluation and Research Director Vinay...

SciSparc Ltd. (NASDAQ:SPRC) traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures Inc. (TSXV:MIZA), a publicly traded firm on Canada's TSX Venture Exchange The Tel Aviv-based pharmaceutical company develops treatments for...

Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday. Check out the current price of BDRX stock here. According to Benzinga Pro data, after closing the regular session at $10.90, up $3.19 or 41.37%, the stock of the biotech then...

Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition. The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro. On Monday,...

Editor’s Note: This article has been updated to correct an earlier inaccuracy regarding the company’s stock trajectory. Nektar Therapeutics Inc. (NASDAQ:NKTR) on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and...

Sanofi SA (NASDAQ:SNY) shared new data from the HS-OBTAIN phase 2a study, which shows that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe...

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro. Monte Rosa announced a collaboration with Novartis AG (NYSE:NVS) to develop novel degraders for immune-...

On Monday, Palantir Technologies Inc. (NASDAQ:PLTR) co-founder Joe Lonsdale urged a tech-driven transformation of the Food and Drug Administration, warning that bureaucratic inertia is putting the U.S. behind China in the biotech race. What Happened: In a blog post, Lonsdale said the FDA's current...

Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) stock experienced a drop of 5.54% on Thursday, followed by a remarkable recovery of 14.29% in after-hours trading. What Happened: Sonnet BioTherapeutics’ stock fell by 5% during regular trading hours on Thursday. The drop was attributed to...

Changpeng Zhao, the founder of cryptocurrency exchange Binance (CRYPTO: BNB), said Tuesday that he made a personal donation of $10 million to support Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin’s biotech initiative. What Happened: Zhao, known popularly as “CZ,” ...

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels. What Happened: Speaking on The Diary of a CEO podcast last...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically...

Verastem Oncology Inc (NASDAQ:VSTM) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant...